Compare GMRS & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMRS | CERS |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.0M | 465.5M |
| IPO Year | 2026 | 1996 |
| Metric | GMRS | CERS |
|---|---|---|
| Price | $11.17 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $18.63 | $5.13 |
| AVG Volume (30 Days) | 726.6K | ★ 1.7M |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $5.13 | $20.82 |
| Revenue Next Year | $5.57 | $9.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $9.00 | $1.38 |
| 52 Week High | $15.98 | $3.47 |
| Indicator | GMRS | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 42.76 |
| Support Level | $9.75 | $2.07 |
| Resistance Level | $14.14 | $3.12 |
| Average True Range (ATR) | 0.51 | 0.09 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 74.45 | 43.24 |
GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.